Centocor Inc. announced Wednesday that the Italiangovernment has granted marketing approval of the company'sHA-1A/Centoxin for the treatment of sepsis syndrome. Thedrug has been approved for use in most major Europeannations, including Germany, the United Kingdom and France.

The FDA decided in April that the Malvern, Pa., company(NASDAQ:CNTO) must complete another Phase III trial beforeCentoxin can be considered for marketing approval.

(c) 1997 American Health Consultants. All rights reserved.

No Comments